Loading...

Survival, risk differences, and risk ratios at 5 years from baseline estimated in the observational emulation of a target trial comparing trastuzumab plus chemotherapy with chemotherapy, NKBC, and seven further Swedish registers, 2008–2015 (main analysis based on 1578 individuals). - Figshare | NLM Dataset Catalog